> Guidant said one of the recommendations it made to physicians in June designed to correct a problem with its recently recalled implantable defibrillators may actually increase risk to patients. Story [1]
> Shire Pharmaceuticals received FDA approval to market Adderall to treat adolescents. Release [2]
> Alpharma is expanding its warning on Kadian. Release [3]
> Myogen has completed enrollment in its Phase III trial of ambrisentan. Release [4]
And Finally... A new study shows a single dose of the anticancer drug carboplatin is as successful and less toxic than previous testicular cancer treatments, and it is comparable to radiation in effectiveness. Story [5]
Links:
[1] http://www.thestreet.com/_googlen/stocks/biotech/10234202.html?cm_ven=GOOGLEN&cm_cat=FREE&cm_ite=NA
[2] http://biz.yahoo.com/ap/050722/shire_pharmaceuticals_adderall.html?.v=1
[3] http://biz.yahoo.com/prnews/050722/nyf052.html?.v=15
[4] http://biz.yahoo.com/prnews/050721/lath090.html?.v=19
[5] http://www.medicalnewstoday.com/medicalnews.php?newsid=27826